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SUMMARY 
While the concept of this syndrome has been described more than 60 years ago, and more 
formally almost 20 years ago, the controversy continues as to its utility, which of the various 
syndrome definitions should be used and their ability to predict diabetes and/or cardiovascular 
disease. The metabolic syndrome, of cardiovascular risk factors, provides an early warning of at 
risk subjects and emphasises the need to treat more aggressively (by at least lifestyle 
modification) patients with multiple abnormalities even though the abnormalities might be slight. 
Further, the syndrome can be easily used in clinical practice and when it is assessed against the 
background of the patient’s age, sex and smoking habits, it provides an evaluation of potential 
cardiovascular risk. Prospective intervention studies are the only means of definitively accepting 
or refuting the usefulness of the syndrome. The metabolic syndrome is an entity which merits 
attention from both the medical profession and public health authorities. 
 
Key Words: Cardiovascular disease • Diabetes • Insulin resistance • Metabolic syndrome 
 
RESUME 
Voilà plus de 60 ans, le concept de syndrome métabolique a été identifié, et plus formellement 
décrit il y a une vingtaine d’années.  La controverse continue quant à l’utilité d’un tel syndrome, 
quant à la définition utilisée et à la capacité des différentes définitions à prédire le diabète 
et/ou les maladies cardio-vasculaires. Le syndrome métabolique indique une alerte précoce pour 
traiter plus agressivement (au moins par des changements de comportement) les patients 
porteurs d’anomalies multiples, même si ces anomalies sont modérées. De plus, le syndrome est 
facile à utiliser en clinique et devrait être mis en parallèle avec l’âge, le sexe et le tabagisme du 
patient pour l’évaluation du risque cardio-vasculaire. Les études prospectives d’intervention sont 
les seules études qui fournissent la preuve de l’utilité du syndrome. Le syndrome métabolique 
mérite toute l’attention de la part du corps médical et des autorités de santé publique. 
 
Mots Clés : Diabète • Insulino-résistance • Maladies cardiovasculaires • Syndrome métabolique  
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Introduction 
The metabolic syndrome groups insulin resistance, hyperinsulinaemia, hyperglycaemia, 
dyslipidaemia (hypertriglyceridaemia and/or hypo HDL-cholesterolaemia), high arterial blood 
pressure and central adiposity. Other abnormalities are also associated with this constellation – 
and may well also be part of this syndrome.  A variety of names have been associated with this 
condition: the pluri-metabolic syndrome, the insulin-resistance syndrome, syndrome X, the 
dysmetabolic syndrome, the metabolic syndrome …  
In itself insulin resistance is not a disease, but rather a risk factor for the syndrome 
abnormalities and it has yet to be demonstrated that it is a risk factor for later cardiovascular 
disease or for diabetes as there are few prospective studies that have measured insulin 
resistance by a validated method.  
At the request of the American Association of Clinical Endocrinologists, in October 2001 
the Centre for Disease Control created the code number 277.7 for the dysmetabolic 
syndrome X in the International Classification of Diseases (ICD-9). This code was recommended 
to be noted if a physician considered that the syndrome was present in a given individual. 
However, a report from the United States indicates that the code is little used [1]. 
  
History of the syndrome 
In 1988 Gerald Reaven presented the Banting Lecture at the American Diabetes Association 
meeting. The title of his lecture was “The Role of Insulin Resistance in Human Disease”, and the 
corresponding article was published in the same year [2].  He gave pathophysiological arguments 
for the existence of a “syndrome X”, in which he included insulin resistance, hyperinsulinaemia, 
hyperglycaemia, dyslipidaemia, arterial hypertension. Several years later, during the Claude 
Bernard Lecture of the European Society for the Study of Diabetes (EASD), Reaven included 
central adiposity in the syndrome, and noted the importance of free fatty acids [3].  While 
Reaven’s description was based on the pathophysiology of insulin resistance, the syndrome that 
he described was not precise and it was not possible to identify individuals as having the 
syndrome: the combination of abnormalities, the number of abnormalities, the thresholds 
defining the abnormalities were not given.  The only abnormality Reaven quantified was insulin 
resistance, which he affirmed to be present in 25% of the adult population. 
Reaven was not the first to propose such a syndrome. Kylin, in 1923, described the 
clustering of hypertension, hyperglycaemia and gout [4].  In France, Jean Vague, at the end of 
the 1940s, documented the association between central adiposity, diabetes, atherosclerosis and 
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gout [5,6]. Later, in 1967, Avogaro et al. described a metabolic syndrome [7] and in 1985 
Michaela Modan proposed that hyperinsulinaemia was the link between hypertension, obesity and 
glucose intolerance [8].  
Following the description of the syndrome by Reaven, it has become a major theme of 
research and of public health interest.  The number of publications on the subject is ample 
evidence of the importance given to the syndrome by clinicians and researchers (over 18,000 
citations to the “metabolic syndrome” in PubMed, December 2006 – with more than 3,000 
citations in 2006 alone). 
 
Arguments for the existence of a syndrome  
The fact that this cluster of abnormalities exists has been well validated by epidemiological 
studies: the abnormalities cluster more frequently than what would be observed if they 
clustered by chance [9]. 
 
Definitions of the metabolic syndrome 
In the absence of a diagnostic test, a number of definitions of the syndrome have been proposed 
(Appendix 1). They come from the World Health Organisation (WHO) [10], the European Group 
for the study of Insulin Resistance (EGIR) [11], J-P Després’ group [12], the National Cholesterol 
Education Program – Adult Treatment Panel III  (NCEP-ATP III) [13]. In 2003 the American 
Association of Clinical Endocrinologists and the American College of Endocrinologists provided a 
position statement of what they entitled the “insulin resistance syndrome” [14] but they did not 
give a precise definition, leaving it to a clinician to decide whether a given individual had the 
syndrome. They recognised that there was no experimental evidence to define diagnostic 
criteria for the syndrome and consequently their definition could not be precise. They conclude, 
that the more abnormalities, the more likely that an individual is insulin resistant.  
 These various definitions include different factors and different thresholds for them.  
For example the first definition, from the WHO, included microalbuminuria, which does not 
appear in the later definitions [10].  The EGIR definition [11] did not include diabetic patients, 
for two reasons – these patients should already be in the health care system, and have their 
health monitored so identification of the syndrome should not be necessary, and secondly, long 
standing diabetic patients have lower insulin levels, which do not reflect the level of insulin 
resistance, a key element of this definition. Finally the simple definition of the 
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“hypertriglyceridemic waist” was origially defined only for men, and it has not generally been 
used as a definition of the syndrome.  
The most recent definitions, both in 2005, are from the International Diabetes 
Federation (IDF) [15, 16] and from the American Heart Association/National Heart, Lung, and 
Blood Institute AHA/NHLBI [17, 18]. 
The differences between these definitions are essentially the thresholds for the 
parameters to define a syndrome abnormality, the number of abnormalities before the syndrome 
is deemed to be present, and whether there is a compulsory abnormality which is required to be 
present.  
Reavens’ arguments were centred around insulin resistance, and the definitions proposed 
by the WHO, EGIR and the IDF have taken this into account – WHO because the presence of 
either insulin resistance or glucose dysregulation were required, EGIR because hyperinsulinaemia 
was a mandatory factor and for the IDF central obesity (as quantified by the waist 
circumference) is mandatory, because of the close association between insulin resistance and 
central adiposity. 
The IDF definition, with its differing thresholds for waist circumference according to 
ethnic group, is likely to become the international norm, as it is supported by several 
international bodies, however, the more recent American definition will probably be used in 
the United States. 
 To define any diagnostic criteria is not easy (for diabetes, the criteria have changed 
over the years). For a syndrome it is even more complicated – what parameters, what thresholds, 
what combinations should be used to define it? In fact a score to evaluate the severity of the 
syndrome, using a combination of continuous variables would be more logical than a syndrome 
defined with arbitrary thresholds. 
 
Frequency of the syndrome and of its abnormalities  
The frequency of the syndrome differs according to the definition, country, sex, age, and even 
according to the region in France.  From the French MONICA study, the frequency of the NCEP-
ATP III defined syndrome, in men aged 35 to 65 years was 26% in Lille, 22% in Strasbourg and 
16% in Toulouse; in women, the corresponding frequencies were 26%, 24% and 13% [19]. (The 
definition used included subjects treated by drugs for hypertension and/or for diabetes). In 
comparison, in the French D.E.S.I.R. Study, of men and women aged 30 to 64 years, the 
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corresponding frequencies were 9% and 6% and if treatment for diabetes and for hypertension 
were also included, the frequencies increased to 15% and to 10%, respectively [20].   
Table 1 shows the means and standard deviations of syndrome parameters from a general 
French population, recruited in Preventive Health Examination Centres in the central western 
part of France. More details of the reference values, and centiles are given on 
www.sciencedirect.com These data are for subjects aged 20 to 74 years, and are given by 5-year 
age classes and by sex; they are from a sample of 130,882 consultants at IRSA (an Institute 
which provides health screening examinations which are financed by the French social security 
system).  In the tables, the column on the right gives the reference values in a population of 
19,126 men and 19,874 women with the same age structure as the French population in the 1999 
census, for subjects aged between 20 and 74 years.  
In this French population, the frequency of the NCEP-ATP III defined syndrome was 
10% in the men and 9% in the women, for the IDF definition 21% and 17% and for the 
AHA/NHBLI definition 18% and 14% respectively (Table 2).  
Note that central adiposity is more common in women than in men – because of the choice 
of the thresholds (Table 2). The NCEP thresholds for the waist ciurcumference > 102/88 for 
men/women were defined because of their relation with obesity, a BMI > 30 kg/m² and/or a high 
waist–hip ratio > 0.95/0.80 men/women [21], and not in relation with the diseases associated with 
the syndrome, diabetes and cardiovascular disease. The IDF waist thresholds were chosen for 
the sensitivity/specificity to screen for a BMI ≥ 25 kg/m2 [21].  
Hypo HDL-cholesterolaemia was also defined according to sex, and is more frequent in 
women than in men. 
It has already been noted that in the French D.E.S.I.R. study [20], high arterial blood 
pressure is more commonly present than in the United States, where the NCEP-ATP III 
definition was conceived: in men 67% vs 38% and in women 44% vs 29%. Such differences have 
been documented in a collaborative study where the prevalences of hypertension were 28% in 
North American countries in comparison to 44% in Europe [22]. 
For the IDF definition of the metabolic syndrome, in comparison with the NCEP-ATP III 
definition, the definitions of all abnormalities are changed, with an increase in frequency for 
each abnormality, in comparison with the NCEP-ATP III definition (Table 2).  The result is a 
doubling of the syndrome frequency. The most marked increases in frequency are associated 
with the waist circumference and fasting glucose (Table 2) where the thresholds have been 
lowered.  For high blood pressure and dyslipidaemia, the changes in frequency are due only to 
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the inclusion of the corresponding treatments – little change for high blood pressure, and a close 
to doubling for both lipid abnormalities; it must be noted that all lipid treatments were included 
in this analysis, as there was no information as to whether the lipid-lowering therapy was 
prescribed for treatment of LDL-cholesterol or for triglycerides/HDL-cholesterol.  
The AHA/NHLBI definition is similar to the NCEP-ATPIII, with the major difference 
being the lowering of the glucose threshold, and in consequence a more than three-fold increase 
in hyperglycaemia. 
 
Consequences of the syndrome 
Reaven described the consequences of the syndrome as cardiovascular disease and diabetes [2].  
A meta-analysis of prospective studies quantified the risks of all cause mortality, of 
morbidity or mortality from cardiovascular diseases and of diabetes from the metabolic 
syndrome as defined by NCEP-ATP III [23]. The relative risks were estimated as: 
1.3 (95% CI: 0.9-1.8), 1.6 (1.3-2.0) and 3.0 (1.9-4.6), respectively. These are certainly dependent 
on the subjects in the study, and if diabetic subjects are included, the risk associated with 
cardiovascular disease is higher than when they are excluded [24].  
There are a number of more recent analyses, one from the Framingham Offspring Cohort 
showed age-adjusted relative risks for CVD, CHD and type 2 diabetes of 2.9, 2.5 and 6.9 for 
men, and 2.2, 1.5 and 6.9 for women [25]. In France the D.E.S.I.R. study has shown that the 
syndrome is predictive of both cardiovascular events and diabetes [26], and in the PRIME study 
of men from France and northern Ireland, the IDF defined syndrome carried a relative risk for 
coronary heart disease of 1.41, the WHO 1.40 and the NCEP 1.46 [27].   
While these relative risks may be statistically significant, a risk equation for 
cardiovascular morbidity or mortality, for example the Framingham or the SCORE risk equations 
[28, 29], are better predictors [30]. However, in the European DECODE study, in men at low 
risk, with an estimated 10-year risk of cardiovascular mortality under 5%, the metabolic 
syndrome had a relative risk of cardiovascular mortality of 2.5 (1.2-5.0) [31,32]. Thus the 
syndrome provides additional predictive information on CVD risk, over and above that given by a 
CVD risk score, and involved 9% of the men. Of the men at high CVD risk (more than 5% over 10 
years, and involving 41% of the men), the syndrome was present in only one third of them. The 
hazards ratios of men at high risk of CVD, whether they had the syndrome or not, and those at 
low risk with the syndrome, were very similar: 2.5, 2.2 and 2.5 respectively, after adjustment 
for age and the recruitment centre. For women there were fewer cardiovascular events, there 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  8/38 
was no relation, and the relative risk was 1.3 (0.4-4.2). However, the waist alone, with the NCEP-
ATP III thresholds, was associated with higher cardiovascular mortality: 2.2 (1.1-4.8) in men and 
2.3 (0.8-6.7) in women, after adjustment for age and recruitment centre, and these two risks 
were not significantly different.  
The metabolic sydnrome carries a much higher risk for diabetes than for CVD. To 
predict incident diabetes, the traditional risk markers of diabetes, such as glucose 
concentrations perform better than the metabolic syndrome [30, 33]. But in the Framingham 
Offspring Study [25], while high fasting glucose carried a hazards ratio of 12.5 (9.1-17.3) for 
high glucose alone, the syndrome had a hazards ratio of 11.0 (8.1-14.9), and the hazards ratio was 
still high, 5.0 (3.7-6.8) if the syndrome was present, but the glucose level low < 6.1 mmol/l. 
Other consequences of the syndrome are hypertension, polycystic ovary syndrome, non-
alcoholic steatosis and chronic renal disease. 
 
Treatment of the syndrome 
As the syndrome does not have a known cause, the cause is not able to be treated. 
To delay the appearance of the syndrome or its manifestations, insulin sensitivity could 
be targeted, by lifestyle modification – loss of weight, increase in physical activity, a healthy 
diet or by pharmacological intervention. There are several medications which target insulin 
sensitivity (Thiazolidinediones, Metformin, … ) and others which help in weight loss (Orlistat, 
Sibutramine, Rimonabant). In the future, there will be more evidence to elucidate whether these 
treatments are effective in delaying the appearance of the metabolic syndrome and in the 
patients with the syndrome, in preventing CVD and diabetes.  
To treat the abnormalities of the metabolic syndrome, the first step is lifestyle 
modification and modest weight may be effective [34]. Drug treatment should be used for the 
specific abnormalities according to current guidelines, and a more aggressive approach may be 
appropriate when more than one abnormality is present. 
 
Statement from the European Association for the Study of Diabetes and the American 
Diabetes Association, 2005 
This joint statement gave a “critical appraisal’ of the metabolic syndrome [35]. It concluded: 
“Until much-needed research is completed, clinicians should evaluate and treat all CVD risk 
factors without regard to whether a patient meets the criteria for diagnosis of the “metabolic 
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syndrome”. The review aimed to argue four points, which are given below along with our 
responses, given in italics:  
 
1. “the metabolic syndrome is not nearly as well defined and characterized as is often assumed” 
RESPONSE: 
The syndrome is certainly not well defined, and it was Reaven who was initially (perhaps 
deliberately) vague with his description of the syndrome [2].  The multiplicity of definitions for 
the syndrome has resulted in confusion and has led to a lack of credibility for the concept as a 
whole. 
 
2.  “the notion that it is a useful marker of CVD risk above and beyond the risk associated with 
its individual components is uncertain” 
RESPONSE 
That the individual components of the syndrome may carry a similar or even higher risk than the 
syndrome has been illustrated in the DECODE study [32]; these analyses also show that men at 
lower estimated risk of cardiovascular death (<5% in 10 years according to the SCORE risk 
equations), who have the syndrome, are at high risk of fatal CVD, of equivalent risk to those at 
higher risk of CVD death, according the European CVD Score equation. Thus, the syndrome – or 
at least the components in the syndrome that are not included in a classical CVD risk score 
(waist circumference in particular) – identifies a group of men at risk. This was not the case in 
the women, but waist circumference was a good marker of fatal CVD risk, in the women at low 
risk (< 5% in 10 years). 
 While CVD risk scores appear to be more closely related with CVD outcomes than the 
syndrome [30], they are rarely used in clinical practice. The syndrome is an easy concept 
enabling a physician to identify patients at risk, with routinely available measures. The 
thresholds of the various parameters enable a quick categorisation of patients, with a large 
waist circumference being a clear first step, which should prompt the search for the cluster of 
metabolic abnormalities. If age, sex and smoking are taken into account along with the syndrome 
abnormalities, the cardiovascular risk can be assessed. An evaluation needs to be made of the 
severity of the various abnormalities, and each one may not carry the same importance. 
 Further, the promotion of the concept of the metabolic syndrome has drawn attention 
to the fact that patients diagnosed with diabetes, hypertension or lipids, should be investigated 
for other abnormalities in the metabolic syndrome cluster. 
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3. “although certain CVD risk factors undoubtedly occur together more often than expected, the 
underlying pathophysiology of the syndrome is unclear” 
RESPONSE 
The clustering of the CVD risk factors, the syndrome abnormalities cannot be disputed – and 
research is needed to elucidate the reasons for this clustering. Given current knowledge, drug 
treatment can only be factor by factor, with appropriate care to choose the treatments which 
do not aggravate the other abnormalities. Research will provide more information, and may also 
provide new molecules to treat the syndrome as a cluster, rather than treating the individual 
abnormalities. In the meantime, the outcome is treated, without consideration of the physiology 
which has led to the condition. Treatment should target insulin sensitivity: increase in physical 
activity and weight loss, and possibly some drugs in the future. 
 
4. “the list of risk factors comprising the cluster is not grounded by well-defined criteria” 
They then state that “the manuscript is a cautionary reminder to practitioners, and an urgent 
call for further research.”  
RESPONSE 
The abnormalities proposed for the definitions of the syndrome have been chosen following 
Reaven [2], and other components have been added or proposed because of their close 
correlation with insulin concentrations or insulin resistance indexes. As argued above, the choice 
of the components, their thresholds or the number of them required for the syndrome is all 
rather arbitrary. Each of the syndrome parameters has a continuous relation with cardiovascular 
disease incidence, thus it is difficult to define a threshold on this basis. The combination of 
abnormalities is also difficult to justify, as is the inclusion of other possible related 
abnormalities. 
 
Other arguments pro- and con for the syndrome  
In a similar vein, a recent article by Reaven is entitled ”The Metabolic Syndrome: Requiescat in 
Pace” [36]. His arguments are targeted on insulin resistance and its relation with clinically 
significant disease with the aim of understanding the pathophysiology. Insulin resistance can 
exist without metabolic clustering. However, Reaven does argue that there is a benefit in 
diagnosing a syndrome to initiate lifestyle changes, but that the use of a precise definition, 
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given the arbitrary nature of the thresholds, may not be appropriate. The diagnosis of diabetes 
relies on somewhat arbitrary, consensual thresholds, and has long proved its usefulness.   
 Greenland poses the clinical question as to whether patient outcome is improved by 
identification of the syndrome – rather than by a classical global CVD risk score [37]. 
The American Heart Association, in particular Grundy et al. [17, 18, 38], and Eckel et al. 
[39], have argued both in scientific journals and in internet newsletters about the utility of the 
syndrome and provided guidelines for its management. 
 
Conclusion. 
While awaiting further knowledge on the causes of the abnormalities of the metabolic syndrome 
and of the metabolic syndrome itself, the metabolic syndrome should be recognized as an entity 
which deserves attention from the medical profession and public health authorities. The 
metabolic syndrome provides an early, simple and cheap warning of patients at risk of 
cardiovascular disease and diabetes, and emphasizes the need to treat more aggressively those 
with multiple abnormalities, even though individually these abnormalities may be slight. While 
there is no clinical trial evidence for the efficacy of such an approach, it is in line, for example, 
with recommendations for the more aggressive treatment of lipids and hypertension in diabetic 
patients. In all cases, the first-line treatment consists of lifestyle modification. Drug 
treatments should be used according to current recommendations for each individual risk factor. 
Additional research is needed to identify new targets for treatments to prevent cardiovascular 
disease, in particular other lipid goals, such as increasing HDL-cholesterol levels once the LDL-
cholesterol goal is achieved.  
In clinical practice either the NCEP-ATP III or the IDF or the AHA/NHBLI definitions 
of the syndrome could be used: the fact that the thresholds and the combinations of 
abnormalities might be arbitrary does not prevent the use of the concept.  For epidemiological 
studies, it would be preferable to report frequencies and outcomes for all three definitions. The 
AHA/NHBLI definition, which retains the higher thresholds values for waist circumference is 
likely, to be adopted in the United States [17, 18]. Certainly, the recognition of a high waist 
circumference as a first abnormality, as in the IDF definition of the syndrome, will enable a 
quick screening of subjects at risk for cardiovascular disease and for diabetes.    
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Table 1 
Means and standard deviations (SD), according to age, of parameters included in the metabolic syndrome in a population of 130,882 consultants, 
65,372 men and 65,510 women, in 2002-2004 at the “Institut inter Régional de la Santé”, (IRSA) an Institute in central-western France which 
provides health examinations. The last column shows the reference values for a population aged 20-74 years with the same age structure as the 
French population in the 1999 census.  More complete information with the distribution of the percentiles is available at www.xxxxxx.   
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Age (years) 
MEN 20-24 
n=3436 
25-29 
n=4812 
30-34 
n=7068 
35-39 
n=8850 
40-44 
n=8885 
45-49 
n=9077 
50-54 
n=9038 
55-59 
n=6474 
60-64 
n=3649 
65-69 
n=2684 
70-74 
n=1399 
20-74 
n=19126 
mean 79 83 86 88 89 91 93 94 95 96 97 89 
WAIST (cm) 
SD 9 10 10 10 10 10 10 10 10 10 10 11 
              
mean 0.91 0.92 0.94 0.96 0.98 1.00 1.02 1.04 1.03 1.04 1.05 0.98 
GLUCOSE (g/l) 
SD 0.11 0.10 0.11 0.12 0.14 0.16 0.19 0.21 0.21 0.22 0.25 0.17 
              
mean 0.84 0.93 1.01 1.06 1.11 1.14 1.15 1.14 1.12 1.09 1.10 1.06 TRIGLYCERIDES 
(g/l) SD 0.47 0.56 0.64 0.63 0.67 0.66 0.66 0.65 0.59 0.53 0.53 0.62 
              
mean 0.51 0.53 0.53 0.54 0.55 0.56 0.56 0.56 0.56 0.56 0.56 0.55 HDL-CHOLESTEROL 
(g/l) SD 0.12 0.13 0.13 0.13 0.14 0.14 0.14 0.13 0.14 0.13 0.14 0.13 
              
mean 127 128 128 129 131 134 137 140 142 146 148 134 SYSTOLIC BLOOD 
PRESSURE (mmHg) SD 10 11 11 12 13 14 15 16 17 18 18 15 
              
mean 73 75 76 78 80 82 83 84 84 84 83 80 DIASTOLIC BLOOD 
PRESSURE (mmHg) SD 8 8 8 9 9 10 10 10 10 10 10 10 
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Age (years) 
WOMEN 20-24 
n=5261 
25-29 
n=5398 
30-34 
n=7264 
35-39 
n=7368 
40-44 
n=8558 
45-49 
n=8879 
50-54 
n=8619 
55-59 
n=6655 
60-64 
n=3509 
65-69 
n=2580 
70-74 
n=1419 
20-74 
n=19874 
mean 72 74 76 77 78 79 81 83 84 85 86 79 
WAIST (cm) 
SD 10 11 11 11 11 12 12 12 12 12 12 12 
              
mean 0.87 0.87 0.89 0.90 0.92 0.94 0.95 0.96 0.97 0.97 0.99 0.93 
GLUCOSE (g/l) 
SD 0.10 0.10 0.10 0.11 0.12 0.15 0.15 0.16 0.17 0.19 0.20 0.15 
              
mean 0.83 0.80 0.79 0.78 0.79 0.82 0.85 0.93 0.97 0.98 1.02 0.85 TRIGLYCERIDES 
(g/l) SD 0.36 0.38 0.38 0.39 0.40 0.45 0.44 0.47 0.48 0.46 0.51 0.43 
              
mean 0.59 0.61 0.61 0.63 0.64 0.65 0.67 0.67 0.67 0.67 0.66 0.64 HDL-CHOLESTEROL 
(g/l) SD 0.14 0.15 0.14 0.15 0.15 0.15 0.16 0.16 0.16 0.16 0.16 0.15 
              
mean 118 117 117 118 121 125 128 132 136 139 143 126 SYSTOLIC BLOOD 
PRESSURE (mmHg) SD 10 11 12 12 14 15 15 16 16 17 18 16 
              
mean 71 72 72 74 76 77 78 79 80 80 80 76 
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mean 71 72 72 74 76 77 78 79 80 80 80 76 DIASTOLIC BLOOD 
PRESSURE (mmHg) SD 8 8 9 9 9 10 9 9 9 9 9 10 
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Table 2 
Frequency of the metabolic syndrome abnormalities and frequency of the syndrome 
defined according to the NCEP-ATP III, the IDF and the AHA/NHLBI definitions, in a 
sample of consultants from IRSA (French Health Examination Centres) in 2002-2004. 
These men and women, aged 20 to 74 years, had the same age structure as the French 
population in the 1999 census. 
 
MEN WOMEN 
NCEP-ATP III defined metabolic syndrome. 
n = 19 126 n = 19 874 
Waist circumference > 102 / 88 cm 12% 20% 
Fasting glucose ≥ 1.10 g/l 12% 6% 
Blood pressure ≥ 130 / ≥ 85 mmHg 66% 43% 
Triglycerides ≥ 1.50 g/l 17% 7% 
HDL-cholesterol < 0.40/0.50 g/l 10% 18% 
NCEP-ATP III syndrome present 10% 9% 
 
 
 
MEN WOMEN 
IDF defined metabolic syndrome 
n = 19 126 n = 19 874 
Waist circumference ≥ 94 / 80 cm 33% 40% 
Fasting glucose ≥ 1.00 g/l or previously diagnosed 
type 2 diabetes 
35% 18% 
Raised blood pressure:  
SBP ≥ 130 or DBP ≥ 85 mmHg or treatment of 
previously diagnosed hypertension 
67% 44% 
Raised triglycerides ≥ 1.5 g/l or a specific treatment 
for this lipid abnormality*  
23% 14% 
Reduced HDL-cholesterol < 0.4/0.5 g/l (men/women) 
or a specific treatment for this lipid abnormality* 
18% 24% 
IDF syndrome present‡ 21% 17% 
 
*  any lipid treatment was included here    
‡  if treated for lipids, only counted for the hypertriglyceridaemia abnormality 
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MEN WOMEN 
AHA/NHLBI defined metabolic syndrome 
n = 19 126 n = 19 874 
Waist circumference > 102 / 88 cm 14% 22% 
Fasting glucose ≥ 1.00 g/l or previously diagnosed 
type 2 diabetes 
35% 18% 
Raised blood pressure:  
SBP ≥ 130 or DBP ≥ 85 mmHg or drug treatment 
for hypertension 
67% 44% 
Raised triglycerides ≥ 1.5 g/l or drug treatment for 
elevated triglycerides  
23% 14% 
Reduced HDL-cholesterol < 0.4/0.5 g/l (men/women) 
or drug treatment for reduced HDL cholesterol 
18% 24% 
AHA/NHLBI syndrome present‡ 18% 14% 
 
*  any lipid treatment was included here    
‡  if treated for lipids, only counted for the hypertriglyceridaemia abnormality 
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Appendix 1 
DEFINITIONS OF THE SYNDROME 
 
WHO definition of the metabolic syndrome, 1999 [10] 
Glucose intolerance, IGT or diabetes mellitus and/or insulin resistance together with two or 
more of the other components listed below:  
• Impaired glucose regulation or diabetes 
• Insulin resistance (under hyperinsulinaemic, euglycaemic conditions, glucose uptake below 
lowest quartile for background population under investigation) 
• Raised arterial pressure ≥ 140 / 90 mm  
• Raised plasma triglycerides (≥ 1.7 mmol/l  (1.5 g/l) and/or low HDL-cholesterol  (< 0.9 mmol/l 
(0.35 g/l) men: < 1.0 mmol/l (0.39 g/l) women)  
• Central obesity: (men: waist to hip ratio > 0.90; women: waist to hip ratio > 0.85 and/or 
BMI > 30 kg/m2 
• Microalbuminuria (urinary albumin excretion rate ≥ 20 µg/min or albumin:creatinine ratio 
≥ 30 mg/g) 
  
EGIR Syndrome d’Insulino-Résistance, 1999 [11] 
Defined only for non-diabetic subjects. 
Insulin-resistance (defined by hyperinsulinaemia  - above the third quartile of the fasting insulin 
concentration in non-diabetic subjects, sexes and all ages combined) plus two abnormalities 
among:  
• Central obesity: waist circumference ≥ 94 / 80 cm (men / women) 
• Dyslipidaemia: high triglycerides: ≥ 2.0 mmol/l  (1.8 g/l) and/or low HDL-cholesterol: < 1.0 
mmol/l (0.40 g/l) or treatment for dyslipidaemia 
• Hyperglycaemia: fasting plasma glucose ≥ 6.1 mmol/l (1.1 g/l) but < 7.0 mmol/l (1.26 g/l) 
• Hypertension: systolic/diastolic ≥ 140 and/or 90 mmHg  or treatment for hypertension 
 
Després’ Group, the hypertriglyceridemic waist, 2000 [12] 
Defined only for men  
• Waist ≥  90 cm 
• Triglycerides ≥ 2.0 mmol/l (1.75 g/l) 
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NCEP-ATP III definition of the metabolic syndrome, 2001 [13] 
Three or more of the following risk factors: 
• Abdominal obesity: waist circumference > 102 / 88 cm (men/women)  
• Triglycerides ≥ 1.50 g/l (1.69 mmol/l) 
• HDL-cholesterol < 0.40 / 0.50 g/l (1.04 / 1.29 mmol/l) (men/women) 
• Blood pressure ≥ 130/ ≥ 85 mmHg 
• Fasting glucose ≥ 1.10 g/l (6.1 mmol/l) 
 
American Association of Clinical Endocrinology, American College of Endocrinology (ACE) 
[14] 
ACE Position Statement on the insulin resistance syndrome*, 2002 
• Abnormalities of the insulin resistance syndrome 
• Triglycerides ≥ 1.50 g/l (1.7 mmol/l) 
• HDL-cholesterol < 0.40 / 0.50 g/l  (1.04 / 1.29 mmol/l) (men/women) 
• Blood pressure > 130 / 85 mmHg 
• Glucose:  fasting  1.10 – 1.25 g/l (6.1 – 6.9 mmol/l), 2 hours post-glucose challenge 1.40 – 2.00 
g/l (7.8 – 11.1 mmol/l) 
 
*The diagnosis of the insulin resistance syndrome must be based on the professional opinion of 
the physician.  
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International Diabetes Federation (IDF) [15, 16] 
Consensus worldwide definition of the metabolic syndrome, 2005  
Central obesity *† – ethnic specific  
Europids ≥ 94 / 80 cm (men / women) (In the USA the ATP III (102 male, 88 female) are 
likely to be used for clinical purposes)  
South Asians ≥ 90 / 80 cm (men / women) 
Chinese ≥ 90 / 80 cm (men / women) 
Japan ≥ 85 / 90 cm (men / women) 
Ethnic Central and South Americans: use South Asians recommendations 
Sub-Saharan Africans: use Europid recommendations 
Eastern Mediterranean and Middle East (Arab): use Europid recommendations 
 
plus any two of the following four factors:  
• raised triglycerides level: ≥ 1.50 g/l (1.7 mmol/l) or a specific treatment for this lipid 
abnormality (given as > 1.50 g/d in [16]) 
• reduced HDL-cholesterol: < 0.40/0.50 g/l (1.03 / 1.29 mmol/l)  (men/women) or a treatment 
specific for this lipid abnormality 
• raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg  or treatment of 
previously diagnosed hypertension 
• raised fasting plasma glucose ≥ 1.00 g/l (5.6 mmol/l) or previously diagnosed type 2 diabetes.  
 
American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI) 
diagnostic criteria for Metabolic Syndrome 2005 [17, 18] 
Three or more of the following risk factors: 
• Elevated waist circumference: > 102 / 88 cm (men / women)  
• Elevated triglycerides > 1.50 g/l (1.7 mmol/l) or drug treatment for elevated triglycerides 
• Reduced HDL-cholesterol < 0.40 / 0.50 g/l (1.04 / 1.29 mmol/l) (men/women) or drug 
treatment for reduced HDL-cholesterol (there is an incorrect conversion from mg/dl to 
mmol/l, and the correction conversion is 1.03 / 1.29 mmol/l) 
• Elevated blood pressure ≥ 130 or ≥ 85 mmHg or drug treatment for hypertension 
• Elevated fasting glucose ≥ 1.00 g/l (5.6 mmol/l) or drug treatment for elevated glucose 
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TO BE PUT ONTO A WEB SITE 
 
 
 
Distribution of the centiles, means and standard deviations, according to age, of 
parameters included in the metabolic syndrome. Population is 130,882 
consultants, 65,372 men and 65,510 women, examined in 2002-2004 at the 
“Institut inter Régional de la Santé”, (IRSA) an Institute in central-western 
France which provides health examinations financed by the French social 
security system. The last column shows the reference values for a population 
aged 20-74 years with the same age structure as the French population 
according to the 1999 census. 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  27/38 
 
 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  28/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  29/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  30/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  31/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  32/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  33/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  34/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  35/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  36/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  37/38 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
14/11/2007  38/38 
 
H
AL author m
anuscript    inserm
-00188846, version 1
H
AL author m
anuscript    inserm
-00188846, version 1
